| Entries |
| Document | Title | Date |
|---|
| 20080261955 | Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression - In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA:5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention of various diseases and disorders associated with noradreanaline reuptake, such as ADHD, CFS, fibromyalgia, and depression with pain. | 10-23-2008 |
| 20080293695 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance - Drug substances comprising a pharmaceutically acceptable organic acid addition salt 6f amine containing pharmaceutically active compounds useful for the treatment of a therapeutic ailment administration and exhibiting prophylactic properties when employed in non-therapeutic administration. | 11-27-2008 |
| 20080312212 | Organic Compounds - A compound of formula (I) | 12-18-2008 |
| 20080318931 | Treatment of Disorders and Diseases of the Colon - A method and a composition for the treatment of an Inflammatory Bowel Disease (IBD) or intestine polyposes is described. The method includes the local administration to the colon of a therapeutically effective amount of at least one Selective Serotonin Reuptake Inhibitor (SSRI) or at least one tricyclic antidepressant (TCA). | 12-25-2008 |
| 20080318932 | Sodium Channel Blocker Compositions and the Use Thereof - Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion. | 12-25-2008 |
| 20090005360 | Modified release preparations containing oxcarbazepine and derivatives thereof - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 01-01-2009 |
| 20090048235 | SUBSTITUTED 5-VINYLPHENYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS - This invention is directed to a cannabinoid modulator compound of formula (I): | 02-19-2009 |
| 20090048236 | NEW PHENYLALANINE DERIVATIVES - Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the α4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which α4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection. | 02-19-2009 |
| 20090054404 | USE OF R-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN | 02-26-2009 |
| 20090082335 | DEUTERIUM-ENRICHED OXCARBAZEPINE - The present application describes deuterium-enriched oxcarbazepine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
| 20090099154 | Pharmaceutical Sustained Release Compositions and Processes Thereof - Pharmaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, solvates, or salts thereof; preferably an antiviral active agent is provided. Also provided is a process of preparation of such composition and method of using them. The sustained release compositions of the present invention are able to deliver the active agent in a desired manner for an extended period of time. | 04-16-2009 |
| 20090105222 | PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISORDERS, INCLUDING STRESS-RELATED DISORDERS - Methods for the prevention or treatment of stress-related disorders by administering a therapeutically effective amount of a dual serotonin/norepinephrine reuptake inhibitor to an individual under stress are described. A triple monoamine reuptake inhibitor for serotonin/noradrenaline/dopamine may also be administered to an individual at risk for a stress-related disorder. In a preferred embodiment the compound is milnacipran and is prophylactically administered at an effective amount to delay or prevent stress-related disorders in an individual at risk. | 04-23-2009 |
| 20090105223 | Compound Having Activity Of Blocking NMDA Receptor Channel, and Pharmaceutical Agent Using The Same - To provide a novel compound having NMDA receptor channel blocking activity, and also a pharmaceutical agent comprising the compound. | 04-23-2009 |
| 20090143360 | Oxcarbazepine Formulation - The present invention relates to novel uncoated, color-stable tablet formulations comprising oxcarbazepine, a disintegrant and iron oxide pigments. The oxcarbazepine of the present invention has a particle size of about 14 to about 30 microns with a maximum residue on a 40 micron sieve from about 10% to about 35%. The present invention further provides for a process of preparing the tablet formulations, and a method of treating mammals in need of oxcarbazepine with the novel formulation. | 06-04-2009 |
| 20090143361 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 - The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical compositions which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating central nervous system disorders, obesity, and metabolic disorders. | 06-04-2009 |
| 20090143362 | CARBAMAZEPINE FORMULATIONS - The present invention relates to a process for preparing a pharmaceutical composition comprising carbamazepine that has a constant release profile. | 06-04-2009 |
| 20090176760 | TRICYCLIC COMPOUNDS - The present invention provides a PPAR γ agonist comprising, as an active ingredient, a tricyclic compound represented by the formula (I) | 07-09-2009 |
| 20090192142 | USE OF CARBAMAZEPINE DERIVATIVES FOR THE TREATMENT OF AGITATION IN DEMENTIA PATIENTS - The present invention relates to the use of a compound of formula (I) wherein R | 07-30-2009 |
| 20090209516 | 9-AMINO-ACRIDINE DERIVATIVES AND METHOD OF TREATING AUTOIMMUNE DISEASES USING THE SAME - The invention relates to compounds according to general formula (1) and/or their enantiomers, diastereomers, and their pharmaceutically compatible salts, and their use to manufacture a medication as well as medications. The compounds are suited for treatment of diseases connected with misfolded proteins. | 08-20-2009 |
| 20090209517 | Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders - This invention relates to the use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the manufacture of various medicaments for treating neuropathic pain and for treating neurological disorders which involve both motor impairment and neuropathic pain. | 08-20-2009 |
| 20090258859 | METRONIDAZOLE COCRYSTALS AND IMIPRAMINE COCRYSTALS - Cocrystals of metronidazole are described herein. Such cocrystals are a cocrystal of metronidazole with gentisic acid and a cocrystal of metronidazole with gallic acid. Cocrystals of imipramine hydrochloride are also described. Such cocrystals are a cocrystal of imipramine hydrochloride with (+)-camphoric acid, a cocrystal of imipramine hydrochloride with fumaric acid, and a cocrystal of imipramine hydrochloride with 1-hydroxy-2-naphthoic acid. | 10-15-2009 |
| 20090258860 | XANTHINE DERIVATIVES FOR THE TREATMENT OF VASCULAR DEPRESSION - Methods and compositions are provided for treating vascular depression. The methods involve administering to a subject in need thereof a xanthine derivative in a therapeutically effective amount to treat vascular depression, particularly the xanthine derivatives pentoxifylline or propentofylline. The methods may further include administration of an additional therapeutic agent in combination with the xanthine derivative selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), and a drug used in the treatment of cerebrovascular disease. Compositions of the invention include pharmaceutical compositions and kits for treating vascular depression in a subject in need thereof that include therapeutically effective amounts of a xanthine derivative and an additional therapeutic agent selected from the group consisting of an SSRI, an SNRI, and a drug used in the treatment of cerebrovascular disease. | 10-15-2009 |
| 20090306049 | Treatment of Barrett's Esophagus - The invention relates to the field of biochemistry and medicine. More specifically, the invention relates to the treatment of epithelial changes in the esophagus. Even more specific, the invention relates to the treatment of Barrett's esophagus. The invention provides a method for at least in part decreasing Barrett's esophagus present in an animal comprising at least in part inhibiting Notch pathway activation in said animal. Preferably, said inhibition of Notch pathway activation is accomplished via a g-secretase inhibitor. | 12-10-2009 |
| 20090306050 | TREATMENT AND PREVENTION OF DEPRESSION WITH PAIN, DEPRESSION SECONDARY TO PAIN, AND OF NEUROPATHIC PAIN - In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA: 5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention of various diseases and disorders associated with noradrenaline reuptake, such as pain predominant-type depression, depression secondary to chronic or neuropathic pain, and neuropathic pain itself. | 12-10-2009 |
| 20090306051 | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders - The present invention relates to methods and compositions for treating CNS-related disorders. | 12-10-2009 |
| 20100029618 | ALPHA-2 RECEPTOR PAN AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN - Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an pan-alpha-2 adrenergic receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed. | 02-04-2010 |
| 20100035860 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY - The invention relates to the use of protein tyrosine phosphatase inhibitors for the promotion of physiological cardiac hypertrophy and the treatment of pathological cardiac hypertrophy. | 02-11-2010 |
| 20100048538 | Therapeutical Uses of Eslicarbazepine - New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions, selected from epilepsy, central and peripheric nervous system disorders, affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neurophatic pain and neuropathic pain-related disorders, sensorimotor disorders, vestibular disorders, and nervous function alterations in degenerative and post-ischemic diseases. Preferably the intractable condition is, at least in part, caused by an overexpression of P-gp or MRP. | 02-25-2010 |
| 20100063029 | USE OF S-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE FOR THE TREATMENT OF ANXIETY AND BIPOLAR DISORDERS - The present invention relates to the use of a racemate of the compound of formula (I) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said anantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders. | 03-11-2010 |
| 20100087422 | TREATMENT OF ADHD - A method is described for treating attention deficit hyperactivity disorder (ADHD), by administering to the individual an anti-epileptic mood stabiliser at a dose which is sub-therapeutic for mood stabilisation, optionally in combination with a psychostimulant. Also described is a method of improving reading comprehension and/or fluency in an individual suffering from learning difficulties which method comprises administering to the individual an anti-epileptic mood stabiliser. | 04-08-2010 |
| 20100120744 | ACETAMIDOPROPANE MODULATORS OF NMDA RECEPTORS - The present invention relates to new acetamidopropane modulators of NMDA receptor, pharmaceutical compositions thereof, and methods of use thereof. | 05-13-2010 |
| 20100120745 | ANTI-ANGIOGENIC AGENTS AND METHODS OF USE - The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadine, Perphenazine, Bithionol, and Clomipramine. | 05-13-2010 |
| 20100120746 | USE OF R-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN - The present invention relates to the use of a mixture of the enantiomers of a compound of formula I | 05-13-2010 |
| 20100160295 | TREATMENT OF RESTLESS LEG SYNDROME AND SLEEP DISORDERS - Methods of preventing and/or treating at least one symptom of Restless Leg Syndrome (RLS) and its related disorders, including disorders such as periodic limb movements in sleep (PLMS) and periodic limb movement disorder (PLMD), are disclosed. The methods comprise identifying a host, afflicted with Restless Leg Syndrome (RLS) and its related disorders; and administering to the host a pharmaceutically effective amount of a 4-hydroxyphenylpyruvate dioxygenase. Also provided are methods and compositions for treating/preventing sleep disorders, and methods and compositions for improving sleep quantity and adequacy. | 06-24-2010 |
| 20100160296 | USE OF IMIPRAMINE BLUE AND ANALOGS THEREOF IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, and parasitic infections. The compounds are triphenyl methane analogs of imipramine blue and analogs thereof, as defined herein. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 06-24-2010 |
| 20100173893 | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation - A process for preparing a compound of the formula IA or IB: | 07-08-2010 |
| 20100184744 | METHOD OF PREPARING A PHARMACEUTICAL CO-CRYSTAL COMPOSITION - The present invention relates to a method of preparing a pharmaceutical co-crystal composition, said method comprising the steps of: a. simultaneously contacting a supercritical or liquefied gas with solid particles of a pharmaceutically active component and with solid particles of a co-builder to form a co-crystallisation medium containing dissolved pharmaceutically active component and dissolved co-builder as well as solid particles of the pharmaceutically active component and solid particles of the co-builder; b. transforming the solid particles of the pharmaceutically active component and the solid particles of the co-builder into co-crystals of said pharmaceutically active component and said co-builder by keeping the supercritical or liquefied gas in a supercritical or liquid state until at least 80 wt. % of the pharmaceutically active component is incorporated in the crystal matrix of said co-crystals; and c. separating said co-crystals from the supercritical or liquefied gas wherein at least a fraction of the pharmaceutically active component and at least a fraction of the co-builder remain in an undissolved state during the co-crystallisation. The present method enables easy preparation of a pharmaceutical co-crystal composition containing virtually no solvent residue and can suitably be used to prepare co-crystals of highly labile pharmaceutically active components. | 07-22-2010 |
| 20100197663 | METHOD AND COMPOSITIONS FOR TREATMENT OF PAINFUL DISORDERS - Chronic pain is treated with a combination of a standard dose of a non-narcotic analgesic and a low dose of a tricyclic antidepressant compound. The invention is effective in the treatment of chronic pain associate with neuropathic or fibromuscular disorders, where such pain has been unresponsive to non-narcotic analgesics alone. | 08-05-2010 |
| 20100216776 | Assays for S100 inhibitors - Provided are methods of determining whether a compound is an inhibitor of an S | 08-26-2010 |
| 20100222327 | Methods of Preparing Pharmaceutical Compositions Comprising Eslicarbazepine Acetate and Methods of Use - The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate. | 09-02-2010 |
| 20100267695 | FUSED INDANE COMPOUND - [Problems] To provide a compound which is useful as an NMDA receptor antagonist. | 10-21-2010 |
| 20100292216 | Methods and Compositions for the Treatment of Psychiatric Conditions - This invention relates to methods and compositions for treating psychiatric conditions, such as depression. | 11-18-2010 |
| 20100292217 | RANOLAZINE FOR THE TREATMENT OF CNS DISORDERS - The present invention relates to a method for CNS disorders such as epilepsy and migraine comprising the administration of a therapeutically effective amount of ranolazine. | 11-18-2010 |
| 20100298296 | Oligomer-Tricyclic Conjugates - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water soluble oligomer. | 11-25-2010 |
| 20100305103 | GENES DIFFERENTIALLY EXPRESSED IN BIPOLAR DISORDER AND/OR SCHIZOPHRENIA - This invention provides molecular markers that are prognostic and/or diagnostic for a psychiatric disorder. In particular, genes are identified whose expression is altered in schizophrenia and/or bipolar disorder thereby providing prognostic and diagnostic markers for the disorder. In addition genes are identified whose dysregulation provides markers that allow diagnostic distinction between schizophrenia and bipolar disorder. | 12-02-2010 |
| 20110028453 | Treating Negative Symptoms of Schizophrenia Associated with Defective Neuregulin 1 - Use of a compound that is a serotonin transporter inhibitor, a selective norepinephrine reuptake inhibitor, or a 5-HT | 02-03-2011 |
| 20110053914 | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic - A pharmaceutical combination comprising: | 03-03-2011 |
| 20110059949 | PROPHYLAXIS AND TREATMENT OF INFECTIOUS DISEASES - The invention relates to the use of inhibitors of acid sphingomyelinase and/or of inhibitors of products of the reaction catalyzed by this enzyme, for the prophylaxis and/or treatment of infectious diseases and/or diseases which are influenced by infections during the course thereof. The cited products especially include ceramide. Preferrably neutralizing antibodies and/or antidepressants, especially tricyclic and/or tetracyclic antidepressants, are used as inhibitors. | 03-10-2011 |
| 20110071137 | PROCESS FOR PREPARING SUSTAINED RELEASE TABLETS - The present invention relates to a novel process for preparing sustained release tablets containing medicinal compounds and the products prepared by said process. The present invention is directed to a method of preparing a sustained release pharmaceutical composition having a predetermined drug release profile, but which is deviated therefrom by adding a tableting effective amount of a water insoluble or partially insoluble cellulose, to said pharmaceutical composition comprised of a drug in a therapeutically effective amount, and sustained release carrier present in amounts effective retard the release of the drug from the pharmaceutical composition and said cellulose, the latter being present in an aqueous system, the improvement comprising adding to the composition an effective amount of maltodextrin to retard the increase on the rate of release of the drug from the addition of said cellulose thereto. | 03-24-2011 |
| 20110071138 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PREMATURE EJACULATION - The present invention provides an oral pharmaceutical composition for the treatment of premature ejaculation, and the composition provides the effective and excellent treatment of premature ejaculation as well as reduced side effects like nausea, vomiting, drowsiness, sedation effect, awakening effect, and weight-loss etc. | 03-24-2011 |
| 20110086845 | Compositions and Methods for Treating Neurodegenerating Diseases - This invention provides agents, compositions, pharmaceutical compositions and methods for treating or slowing the progression of a neurodegenerating disease, such as Alzheimer's disease and a demyelinating disease. | 04-14-2011 |
| 20110136790 | Tricyclic Heterocyclic Derivatives and Methods of Use - The present invention relates to novel Tricyclic Heterocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Heterocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. R1 is formula (Ia), (Ib) or (Ic); R | 06-09-2011 |
| 20110152249 | EVALUATING CENTRAL NERVOUS SYSTEM - Evaluating hemodynamic parameters in the cortex can be used as an objective test for CNS activity, e.g., pain. | 06-23-2011 |
| 20110160186 | Methods of Treating CYP2D6 Alternative Metabolizers - The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene. | 06-30-2011 |
| 20110190268 | Novel Benzimidazole Linked Pyrrolo[2,1-c[1,4] Benzodiazepine Hybrids as Potential Antitumour Agents and Process for the Preparation Thereof - The present invention provides a compounds of general formula (8), (11) and (14), useful as potential antitumour agents against human cancer cell lines. The present invention further provides a process for the preparation of pyrrolo [2,1-c][1,4]benzodiazepine hybrids of general formula (8), (11) and (14). | 08-04-2011 |
| 20110201598 | Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer - A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds' ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. It has been further tested in pancreatic cancer, breast cancer, and SCLC cell lines. The compounds show utility for inhibition of survival and proliferation of tumour cells. | 08-18-2011 |
| 20110207718 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS - Methods of treating psychiatric disorders are provided which include administration of one or more anti-epileptic agents and, optionally, one or more a psychostimulants. Also provided are pharmaceutical compositions comprising, in combination, one or more anti-epileptic agents and one or more psychostimulants. Psychiatric disorders include those associated with impaired cognitive processing, degenerative disorders such as Mild Cognitive Impairment, Parkinson's disease, dementia, non-compliance with therapeutic regimes and eating disorders, although without limitation thereto. | 08-25-2011 |
| 20110212944 | 2-OXO-1-PYRROLIDINE DERIVATIVES - This invention relates to novel 2-oxo-1-pyrrolidines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as a synaptic vesicle protein 2A (SV2A) ligand and/or a sodium channel blocker. | 09-01-2011 |
| 20110245235 | Systems, Methods, and Devices for Rehabilitation of Auditory System Disorders Using Pharmaceutical Agents and Auditory Devices - The present inventions provide combination therapies, kits, and methods for providing relief and/or for improving one or more symptoms associated with an auditory system disorder in a subject diagnosed with the auditory system disorder, comprising an effective amount of at least one pharmaceutical agent and at least one auditory system disorder device, as well as methods for using at least one pharmaceutical agent and/or at least one auditory system disorder device in the manufacture of said kits. | 10-06-2011 |
| 20110257160 | QUINOLINE DERIVATIVES AND USES THEREOF - This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQ | 10-20-2011 |
| 20110294787 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES - The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use. | 12-01-2011 |
| 20110301147 | Modified release preparations containing oxcarbazepine and derivatives thereof - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 12-08-2011 |
| 20110319388 | METHODS OF PREPARING PHARMACEUTICAL COMPOSITIONS COMPRISING ESLICARBAZEPINE ACETATE AND METHODS OF USE - The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate. | 12-29-2011 |
| 20110319389 | METHODS AND COMPOSITIONS FOR TREATING FATIGUE ASSOCIATED WITH DISORDERED SLEEP USING VERY LOW DOSE CYCLOBENZAPRINE - The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment. | 12-29-2011 |
| 20120022047 | PROCESS FOR THE PURIFICATION OF ESLICARBAZEPINE ACETATE - The present invention relates to the purification and particle size of eslicarbazepine acetate. The present invention also relates to the physical characteristics of solid state eslicarbazepine acetate, and pharmaceutical compositions containing the same. | 01-26-2012 |
| 20120071464 | METHOD OF TREATMENT OF OBSESSIVE COMPULSIVE DISORDER WITH ONDANSETRON - Methods for treating obsessive compulsive disorder are described. In one method, a serotonin reuptake inhibitor (SRI) and ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder. The step of administering the SRI and the ondansetron is then repeated for more than seven days. In another method, an SRI, a neuroleptic, and ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder. The step of administering the SRI, the neuroleptic, and the ondansetron is then repeated for more than seven days. In another method, ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessive compulsive disorder for more than seven days. The ondansetron or pharmaceutically acceptable salt thereof may be administered as a pharmaceutically effective dose up to about 1.5 mg (free-base equivalent). | 03-22-2012 |
| 20120071465 | MITOCHONDRIAL ACTIVITY INHIBITORS OF CANCER-INITIATING CELLS AND USE THEREOF - The present invention relates to the compounds useful in the prevention and/or treatment of tumours. More specifically the present invention relates to inhibitors of the activity of the electron transport chains and/or the mitochondrial TCA cycle in glioma-initiating cells (GICs) for use in a method for preventing and/or treating tumours presenting glioma-initiating cells (GICs) in a subject who has undergone a prior removal of a tumour glioma bulk. The present invention further provides a pharmaceutical composition containing the inhibitors of the invention and a screening method for identifying the inhibitors of the invention. | 03-22-2012 |
| 20120083487 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY - Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like. | 04-05-2012 |
| 20120129839 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN POLYMERIZATION - The present invention relates to methods of treatment of clinical disorders associated with protein polymerization comprising administering, to a subject, an effective amount of carbamazepine, oxcarbazepine or another carbamazepine-like compound. It is based, at least in part, on the discovery that, in cells having a genetic defect in α1-antitrypsin, carbamazepine was able to decrease levels of the mutant protein. Furthermore, carbamazepine reduced the hepatic load of mutant α1-antitrypsin and the toxic effect of that mutant protein accumulation, hepatic fibrosis, in vivo using a mouse model of the disease. As patients having this defect in α1-antitrypsin exhibit toxic accumulations of the protein, treatment according to the invention may be used to ameliorate symptoms and signs of disease. | 05-24-2012 |
| 20120214797 | Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia - The use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia. Useful 5H-dibenz/b,f/azepine-5-carboxamide derivatives include compounds of the formula (I): | 08-23-2012 |
| 20120232060 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 09-13-2012 |
| 20120283246 | NOVEL PARENTERAL CARBAMAZEPINE FORMULATION - The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration. | 11-08-2012 |
| 20120322792 | Method and Compositions for Treating Cancer and Related Methods - The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib a tricyclic agent compound, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib, and wherein the tricyclic agent is administered in an amount that does not lead to a substantial central nervous system effect. In additional aspects, the invention relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy. | 12-20-2012 |
| 20120329783 | COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS - The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro. | 12-27-2012 |
| 20130012497 | METHODS FOR DETECTING ADHD SUSCEPTIBILITY AND PREDICTING SEVERITY AND LONG TERM OUTCOME OF ADHD SYMPTOMS - The invention provides methods of determining an altered susceptibility to develop ADHD, methods of predicting or determining the severity of symptoms of ADHD and associated disorders, and methods of treatment based on the presence or absence of one or more alleles of single nucleotide polymorphism (SNP) markers. | 01-10-2013 |
| 20130040939 | Oral Suspension Formulations of Esclicarbazepine Acetate - An oral suspension formulation comprising eslicarbazepine acetate and a pharmaceutically acceptable liquid vehicle. | 02-14-2013 |
| 20130072475 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ASSOCIATED DISORDERS - This disclosure provides methods for treating asthma or an associated disorder in a patient in need thereof, by administering to the patient an effective amount of an autophagy inducing agent, thereby treating the asthma or the associated disorder. Disorders that can be treated include, allergic asthma, chronic obstructive pulmonary disease, lung inflammation, respiratory tolerance and a lung infection or disorder. | 03-21-2013 |
| 20130072476 | NOVEL PARENTERAL CARBAMAZEPINE FORMULATION - The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration. | 03-21-2013 |
| 20130109674 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING TRIGEMINAL AUTONOMIC CEPHALGIAS, MIGRAINE, AND VASCULAR CONDITIONS | 05-02-2013 |
| 20130123240 | METHOD OF USING BIOTHIONOL AND BIOTHIONOL-LIKE COMPOUNDS AS ANTI-ANGIOGENIC AGENTS - The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadinc, Perphenazine, Bithionol, and Clomipramine. | 05-16-2013 |
| 20130143868 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS - The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD). | 06-06-2013 |
| 20130143869 | USE OF A CATIONIC AMPHIPHILIC DRUG FOR THE PREPARATION OF A FORMULATION FOR THE REDUCTION OF SUBCUTANEOUS ADIPOSE TISSUE - Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction and/or prevention of subcutaneous adipose tissue with improved effectiveness and better reproducible activity. | 06-06-2013 |
| 20130150348 | Composition - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition. | 06-13-2013 |
| 20130210809 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of Formula (1), wherein M, A and B are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors-subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved. | 08-15-2013 |
| 20130252944 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR | 09-26-2013 |
| 20130252945 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS - An amorphous formulations of a pharmaceutical includes a composition of the formula [A] | 09-26-2013 |
| 20130274248 | Compound Having Activity Of Blocking NMDA Receptor Channel, and Pharmaceutical Agent Using The Same - [PROBLEMS] To provide a novel compound having NMDA receptor channel blocking activity, and also a pharmaceutical agent comprising the compound. | 10-17-2013 |
| 20130317009 | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and an Anticonvulsant - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an anticonvulsant selected from the group consisting of retigabin, lamotrigine, lacosamide, levetiracetam, carbamazepine, sultiame, phenacemide, felbamate, topiramate, pheneturide, brivaracetam, selectracetam, zonisamide, stiripentol, beclamide, mexiletin, ralfinamide, methylphenobarbital, phenobarbital, primidone, barbexaclone, metharbital, ethotoin, phenyloin, amino(diphenylhydantoin) valeric acid, mephenyloin, fosphenyloin, paramethadione, trimethadione, ethadione, ethosuximide, phensuximide, mesuximide, clonazepam, lorazepam, diazepam, clobazam, oxcarbazepine, eslicarbazepine, rufinamide, valproic acid, valpromide, aminobutyric acid, progabide, tiagabine, and the physiologically acceptable salts thereof. | 11-28-2013 |
| 20130345198 | PROCESS FOR THE PREPARATION OF (S)-(+)- OR (R)-(-)-10-HYDROXY DIHYDRODIBENZ[B,F]AZEPINES BY ENANTIOSELECTIVE REDUCTION OF 10,11-DIHYDRO-10-OXO-5H-DIBENZ[B,F]AZEPINES AND POLYMORPHS THEREOF - The present invention provides a novel process for the preparation of substituted optically pure (S)-(+)- or (R)-(−)-10-hydroxy-dihydrodibenz[b,f]azepines or derivatives thereof, starting from 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepines using boronate esters or their derivatives. The present invention also provides use of thus prepared (S)-(+)- or (R)-(−)-10-hydroxy-dihydrodibenz[b,f]azepines for the preparation of their ester such as (S)-(−)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide or (R)-(+)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. The present invention also provides novel solid state crystalline forms J | 12-26-2013 |
| 20140045824 | METHOD FOR PRODUCING COMPLEX CRYSTAL AND METHOD FOR SCREENING COMPLEX CRYSTAL - The present invention relates to a method for producing a complex crystal composed of two or more different compounds, comprising crystallizing the two or more different compounds under a condition at which menthol is heat melted, and a method for screening a complex crystal. In accordance with the method for producing a complex crystal of the present invention, a complex crystal capable of being used as a drug material can be produced rapidly, simply and efficiently. In addition, in accordance with the method for screening a complex crystal of the present invention, a stable complex crystal can be searched, which is industrially useful. | 02-13-2014 |
| 20140057900 | Pro-Neurogenic Compounds - Compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like. | 02-27-2014 |
| 20140080812 | NOVEL PARENTERAL CARBAMAZEPINE FORMULATION - The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration. | 03-20-2014 |
| 20140094449 | TREATMENT OF BIPOLAR DISORDER - The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol mono-phosphatase (IMPase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bi-polar disorder, the compounds having a structure of Formula (I), or is a pharmaceutically acceptable salt thereof; Formula (I); in which: E is S or Se and each of phenyl rings A and B is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from F, Cl and Br; (2) C | 04-03-2014 |
| 20140100219 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 04-10-2014 |
| 20140107104 | COMBINATION MEDICINE FOR TREATMENT OF DEPRESSION - The present invention provides a combination medicine for treatment of depression, comprising a combination of (A1) an antidepressant and either (B1) a dopamine D1 receptor agonist or (C1) a dopamine D1 receptor antagonist; and a method for screening for an antidepressant that in combination with a dopamine D1 receptor agonist provides an improvement in treatment of depression, the method comprising the steps of: administering, to a mammal, (A2) a compound having an antidepressant action and (B1) a dopamine D1 receptor agonist, and detecting a greater increase in depression-related gene expression, dopamine D1 receptor expression and/or dopamine D1 receptor signaling in comparison with the case where (A2) the compound having an antidepressant action or (B1) the dopamine D1 receptor agonist is administered. | 04-17-2014 |
| 20140142087 | INHIBITORS OF PHOSPHATIDIC ACID PHOSPHOHYDROLASE (PAP), INCLUDING D-PROPRANOLOL AND ANALOGS THEREOF, ALONE OR IN COMBINATION WITH DESIPRAMINE, FOR THE TREATMENT OF CANCERS THAT DEPEND ON THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR), ONCOGENIC VARIANTS THEREOF AND OTHER MEMBERS OF THE ErbB/HER FAMILY - Compounds and combinations of them that inhibit phosphatidic phosphohydrolase (PAP) enzymatic activity are formulated into pharmaceuticals useful in cancer treatment. Inhibitors of PAP can be used for blocking the progression of cancers that depend on the epidermal growth factor receptor (EGFR), its oncogenic variants and other members of its ErbB tyrosine kinase receptor family, through induction of their endocytosis, thus making them inaccessible to the extracellular stimuli that promote maintenance and progression of cancer. | 05-22-2014 |
| 20140148441 | 6-((S)-1--ETHYL)-3H-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST - A TARP γ8 dependant AMPA receptor antagonist of the formula: | 05-29-2014 |
| 20140200210 | PHARMACEUTICAL COMPOSITION FOR TREATING PREMATURE EJACULATION AND METHOD FOR TREATING PREMATURE EJACULATION - The present invention relates to a pharmaceutical composition for treating, preventing or improving premature ejaculation, which is taken on demand prior to sexual activity, the composition comprising clomipramine hydrochloride in an amount of 14 to 16 mg, preferably about 15 mg, as an active ingredient. More preferably, the composition of the present invention further comprises pregelatinized starch and sodium starch glycolate. The pharmaceutical composition of the present invention can provide rapid onset of efficacy, reduce a dissolution (absorption) deviation according to the patient's gastrointestinal pH conditions and minimize side effects. | 07-17-2014 |
| 20140213578 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS - Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazine, dibenzoazepine and annulene and similar genera: | 07-31-2014 |
| 20140243319 | TREATMENTS TARGETING GAMMA-SYNUCLEIN EXPRESSION LEVELS - A combination treatment taking advantage of the synergistic effect of inhibiting γ-synuclein expression and chemotherapeutic agents to provide improved treatment of cancers, preferably stage III/IV cancers. A method for identifying improved cancer treatments. | 08-28-2014 |
| 20140288058 | METHODS OF PREPARING PHARMACEUTICAL COMPOSITIONS COMPRISING ESLICARBAZEPINE ACETATE AND METHODS OF USE - The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate. | 09-25-2014 |
| 20140309214 | Therapeutical Uses of Eslicarbazepine - New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions. | 10-16-2014 |
| 20140336181 | Use of polymorphisms for identifying individuals at risk of developing autism - The present invention relates to nucleic-acid based diagnostics and the use of such diagnostics for the diagnosis of developmental disorders. Novel methods of assessing individuals for the risk of developing autism through the identification of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene alone or in combination with other genes associated with methylation pathways are identified. Methods of identifying those individuals that are at increased and/or decreased risk for developing autism are provided. | 11-13-2014 |
| 20140343043 | Composition - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition. | 11-20-2014 |
| 20140343044 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 11-20-2014 |
| 20150018340 | PIPECOLATE-DIKETOAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS - The present invention relates to compounds having a pipecolate diketoamide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said pipecolate diketoamide compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions. | 01-15-2015 |
| 20150065488 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN POLYMERIZATION - The present invention relates to methods of treatment of clinical disorders associated with protein polymerization comprising administering, to a subject, an effective amount of carbamazepine, oxcarbazepine or another carbamazepine-like compound. It is based, at least in part, on the discovery that, in cells having a genetic defect in α1-antitrypsin, carbamazepine was able to decrease levels of the mutant protein. Furthermore, carbamazepine reduced the hepatic load of mutant α1-antitrypsin and the toxic effect of that mutant protein accumulation, hepatic fibrosis, in vivo using a mouse model of the disease. As patients having this defect in α1-antitrypsin exhibit toxic accumulations of the protein, treatment according to the invention may be used to ameliorate symptoms and signs of disease. | 03-05-2015 |
| 20150094301 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 04-02-2015 |
| 20150099739 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 04-09-2015 |
| 20150111878 | COMPOSITIONS AND METHODS FOR TREATING INTESTINAL HYPERPERMEABILITY - The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor. | 04-23-2015 |
| 20150306109 | Compositions Comprising Nicotinic Agonists and Methods of Using Same - The disclosure is directed at least in part to compositions and methods comprising nicotinic agonists for treating e.g., nervous system disorders, in particular, to combination therapies that include a nicotinic agonist (for example, nicotine) and a nicotinic acetylcholine receptor desensitization inhibitor (for example, opipramol). | 10-29-2015 |
| 20150331992 | CANCER PROGNOSIS AND THERAPY BASED ON SYNTHEIC LETHALITY - Systems and methods for identifying synthetic lethal (SL) and synthetic dosage lethal (SDL) interactions and networks are provided. Further provided are methods for predicting cancer gene essentiality, drug efficacy and survival of cancer patients using data-driven identification of synthetic lethality in cancer are provided. Novel drug candidates and drug combinations for use in cancer therapy and method for prioritizing existing cancer therapies are also provided. | 11-19-2015 |
| 20150359748 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 12-17-2015 |
| 20150359800 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 12-17-2015 |
| 20150366876 | Use of Inhibitors of Acid Sphingomyelinase to Treat Acquired and Inherited Retinal Degenerations - A method of treating retinal diseases is disclosed that includes the step of administering an effective amount of a composition including an ASMase inhibitor to a retinal disease patient, wherein at least one disease symptom is either lessened or progression of the symptom is delayed. | 12-24-2015 |
| 20150374712 | Combinations of Dopamine D2 Receptor Blockade With Norepinephrine Reuptake Inhibition and with Norepinephrine Alpha 2 Receptor Blockade - Methods of treating and or preventing substance abuse/dependence, and alcohol abuse/dependence in particular. Combinations of medications are also disclosed. | 12-31-2015 |
| 20160009677 | TRICYCLIC COMPOUND AND USE THEREOF | 01-14-2016 |
| 20160015818 | COMPOSITIONS AND METHODS FOR PHYSIOLOGICAL DELIVERY USING CANNABIDIOL - The present invention relates to compositions and methods for the administration of Cannabinoids to a patient, and in a specific embodiment, the compositions and methods may utilize or include cannabinoids, and one or more active pharmaceutical ingredients, wherein said composition is configured for transdermal or oral delivery. | 01-21-2016 |
| 20160051560 | TREATMENTS INVOLVING ESLICARBAZEPINE OR ESLICARBAZEPINE ACETATE - The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 in a human patient. | 02-25-2016 |
| 20160090379 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISORDERS - The invention relates to the compounds of formula I and formula Ia or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of formula I or formula Ia; and methods for treating or preventing epilepsy, seizures and convulsions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, seizures and convulsions. | 03-31-2016 |
| 20160122332 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention relates to the compounds of formula I and formula IA or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I and formula IA; and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder (ADHD), schizophrenia, neuropathic pain, seizures, bipolar disorder, mania, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, borderline personality disorder, Myotonia congenita and post-traumatic stress disorder. | 05-05-2016 |
| 20160124003 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ATTENTION DEFICIT HYPERACTIVITY DISORDER - The present disclosure relates to methods of identifying subjects who are suffering from, or are susceptible to developing, ADHD. The methods comprise determining whether the subject is an efficient converter of medium chain polyunsaturated fatty acids to long-chain polyunsaturated fatty acids. Also provided are methods of treating ADHD in a subject, comprising administering to the subject an effective amount of a composition comprising long chain omega-3 fatty acids. | 05-05-2016 |
| 20160193169 | Compositions And Methods For Treating Intestinal Hyperpermeability | 07-07-2016 |
| 20160376656 | Single Nucleotide Polymorphism in HLA-B*15:02 and Use Thereof - Disclosed herein is a novel single nucleotide polymorphism (SNP) in HLA-B*15:02 that can be used as a biomarker for carbamazepine-induced severe adverse skin reactions in Asians. Also provided herein are methods and reagents for assessing the specific SNP, and applying the SNP in predicting an increased risk of carbamazepine-induced severe adverse skin reactions. | 12-29-2016 |
